2245. Oral 5-Day Lefamulin for Outpatient Management of Pneumonia Outcomes Research Team (PORT) Risk Class III/IV Community-Acquired Bacterial Pneumonia (CABP): Post Hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Phase 3 Study

BACKGROUND: Site-of-care decisions (e.g., admission vs. outpatient) in CABP management can be challenging for healthcare providers. Here we describe a post hoc analysis of adults with CABP managed as outpatients in the LEAP 2 double-blind, noninferiority, Phase 3 trial. METHODS: LEAP 2 compared the...

Descripción completa

Detalles Bibliográficos
Autores principales: Schranz, Jennifer, Alexander, Elizabeth, Fitts, David, Mariano, David, Meads, Andrew, Sandrock, Christian, Moran, Gregory J, Gelone, Steven P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809828/
http://dx.doi.org/10.1093/ofid/ofz360.1923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809828/
http://dx.doi.org/10.1093/ofid/ofz360.1923

Ejemplares similares